Skip to main content

Currently Skimming:

Impact and Control of Valley Fever: Proceedings of a Workshop - in Brief
Pages 1-13

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 1...
... cases are found in southern Arizona Albert Einstein College of Medicine provided an overview and the San Joaquin Valley region in California. There of the role of fungi in the environment.
From page 2...
... Monk Yun Rou highlighted that the presence in lung tissues of small mammals from museum disease results in significant suffering. With low energy samples (Salazar-Hamm et al., 2022)
From page 3...
... This hypothesis is supported by data between regions, with the vast majority occurring in that show native rodents and their burrows harbor the Southern San Joaquin Valley. However, Cooksey's Coccidioides (Kollath et al., 2020; Salazar-Hamm et research shows that in recent years Valley fever rates al., 2022)
From page 4...
... Gorris from Los Alamos National Laboratory EXPOSURE TO VALLEY FEVER discussed her research on climate change and how it Dave Engelthaler from TGen emphasized that exposure affects Valley fever epidemiology. Coccidioides spp.
From page 5...
... activities that release arthroconidia in the air, to better understand and mitigate occupational risks. PEOPLE AT RISK FOR INFECTION Shawnell Damon from Indian Health Services discussed Daniel Kollath from Northern Arizona University further surveillance of Valley fever in the Navajo Nation.
From page 6...
... In 2015 GENOMIC CHARACTERISTICS OF COCCIDIOIDES SPP. CCHCS initiated a Coccidioides skin test program and Bridget Barker from Northern Arizona University medically restricted residents with negative test results discussed the ecology and evolution of Coccidioides immitis from being placed at PVSP and ASP.
From page 7...
... These mutations affect pathways involved CHALLENGES WITH DIAGNOSTICS FOR VALLEY FEVER in response to β-glucan, including TNFα and H2O2 Fariba Donovan from the University of Arizona College production. Therefore, many relatively common variants of Medicine and the Valley Fever Center for Excellence in disseminated Coccidioides are associated with early discussed current diagnostic challenges for Valley fever.
From page 8...
... This diagnostic allow for a reduction in improper treatment and improve assay has been developed to use urine or serum to detect assessment of disease stage, Bean stated. Coccidioides spp.
From page 9...
... other invasive fungal infections is needed, Rex stated. Unfortunately, there is no easy fix for these challenges.
From page 10...
... Nucleic acid vaccines offer many features that regulatory considerations for the human clinical trials align with what may be needed for an effective Valley for this vaccine include efficiency in collecting clinical fever vaccine, she explained: they can induce Th1/Th17 data, diagnostic precision, the regulatory requirement responses and mucosal immunity, enable multi-antigen for more than one trial, addressing whether to eliminate vaccine composition, are easy to manufacture and scale the population that tests positive on the skin test from up, are amenable to needle-free or self-administration, March 2023 | 10
From page 11...
... The act would establish a fungal immunogen discovery. One caveat is that viral antigens diseases working group and facilitate coordination expressed by nucleic acid vaccines closely mimic viral with NIAID, allow for fast-tracked review of drugs for infections, and with fungal antigens, this may present coccidioidomycosis treatment, and require the Biomedical a new challenge.
From page 12...
... 2022. The air mycobiome is decoupled animal burrows on the ecology and distribution of from the soil mycobiome in the California San Joaquin Coccidioides spp.
From page 13...
... , University of California, Davis Medical Center; BRIDGET BARKER, Northern Arizona University; GAIL SONDERMEYER COOKSEY, California Department of Public Health; KAREN EHNERT, Los Angeles County Department of Public Health; JOHN GALGIANI, University of Arizona College of Medicine, Tucson; STEVEN M HOLLAND, National Institutes of Health; MERITXELL RIQUELME, Centro de Investigación Científica y de Educación Superior de Ensenada; LEONARD SACKS, Food and Drug Administration.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.